Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Eichhorst

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Blood|March 16, 2018
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Bruce D Cheson, Daniel Catovsky, et al.
Cancer Management and Research|December 20, 2019
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced MalignancyPamela Munster, Monica Mita, Amit Mahipal, et al.
Blood|April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
The New England Journal of Medicine|February 20, 2025
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic LeukemiaJennifer R Brown, John F Seymour, Wojciech Jurczak, et al.
Leukemia|July 14, 2019
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLLDeyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, et al.
European Journal of Haematology|February 4, 2024
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemiaSibylle C Mellinghoff, Sandra Robrecht, Rosanne Sprute, et al.
The New England Journal of Medicine|March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyOthman Al-Sawaf, Can Zhang, Tong Lu, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Blood|March 16, 2018
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Bruce D Cheson, Daniel Catovsky, et al.
Cancer Management and Research|December 20, 2019
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced MalignancyPamela Munster, Monica Mita, Amit Mahipal, et al.
Blood|April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
The New England Journal of Medicine|February 20, 2025
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic LeukemiaJennifer R Brown, John F Seymour, Wojciech Jurczak, et al.
Leukemia|July 14, 2019
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLLDeyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, et al.
European Journal of Haematology|February 4, 2024
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemiaSibylle C Mellinghoff, Sandra Robrecht, Rosanne Sprute, et al.
The New England Journal of Medicine|March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyOthman Al-Sawaf, Can Zhang, Tong Lu, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Pageof 12